← SUPERNUS PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $91.2m | $57.3m | $111.0m | $113.1m | $127.0m | $53.4m | $60.7m | $1.3m | $73.9m | ($38.5m) | — | |
| Depreciation, Depletion and Amortization | $2.4m | $8.1m | $7.1m | $6.7m | $18.1m | $32.6m | $85.5m | $84.9m | $80.4m | $91.6m | $101.7m | |
| Amortization of Debt Issuance Costs and Discounts | $520k | $50k | $11.8m | $15.7m | $16.6m | $17.5m | $2.1m | $532k | $0 | $0 | — | |
| Amortization of Intangible Assets | $1.3m | $6.9m | $5.2m | $5.2m | $15.7m | $30.0m | $82.6m | $82.4m | $78.0m | $89.5m | — | |
| Deferred Income Tax Expense (Benefit) | ($41.8m) | $21.2m | ($4.2m) | ($5.8m) | $568k | ($5.0m) | ($26.3m) | ($25.7m) | ($20.1m) | $5.2m | $5.3m | |
| Share-based Payment Arrangement, Noncash Expense | $5.9m | $8.4m | $11.3m | $14.8m | $16.6m | $17.9m | $17.6m | $26.8m | $27.8m | $33.1m | $34.6m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | — | $2.0m | $2.7m | $4.2m | — | |
| Share-based Payment Arrangement, Expense | $5.9m | $8.4m | $11.3m | $14.8m | $16.6m | $17.9m | $17.6m | $26.8m | $27.8m | $56.0m | $34.6m | |
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | $0 | $0 | $0 | $61.2m | |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | — | — | — | — | — | $20.2m | $0 | $0 | — | |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss | — | — | ($8k) | — | — | — | — | $0 | ($9k) | $439k | — | |
| Equity Method Investment, Realized Gain (Loss) on Disposal | — | — | — | — | — | — | $12.9m | $0 | $0 | — | — | |
| Nonoperating Income (Expense) | ($3.8m) | $1.1m | ($4.3m) | — | — | — | — | $8.0m | $16.2m | $13.3m | — | |
| Other Nonoperating Income (Expense) | ($15k) | — | — | ($1.1m) | ($5.0m) | ($12.9m) | $14.6m | $10.5m | $16.2m | $13.3m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $15.6m | $24.1m | $35.9m | ($15.8m) | $34.6m | ($3.9m) | $16.4m | ($18.8m) | ($2.1m) | $22.3m | ($47.4m) | |
| Increase (Decrease) in Inventories | $4.2m | ($497k) | $9.4m | $969k | $10.1m | $14.6m | $17.9m | ($6.1m) | ($15.8m) | $7.5m | ($17.5m) | |
| Inventory Write-down | — | — | — | — | — | — | — | $8.0m | $8.9m | $1.9m | — | |
| Increase (Decrease) in Accounts Payable | $3.5m | ($620k) | ($3.6m) | $7.0m | — | — | — | — | — | — | ($25.8m) | |
| Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Not Previously Recorded | — | — | — | — | — | — | — | $0 | $0 | $0 | — | |
| Net Cash Provided by (Used in) Operating Activities | $66.8m |
$114.6m
+71.59%
|
$129.0m
+12.51%
|
$143.1m
+10.96%
|
$138.4m
-3.30%
|
$127.1m
-8.14%
|
$116.8m
-8.10%
|
$111.1m
-4.91%
|
$172.0m
+54.79%
|
$47.3m
-72.47%
|
$19.9m
-57.93%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $1.6m | $2.0m | $844k | $2.7m | $3.4m | $25k | $412k | $551k | $725k | $1.3m | ($1.1m) | |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded | — | — | — | — | $0 | — | — | — | — | — | — | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | — | — | — | $0 | ($9k) | ($439k) | — | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | — | — | — | — | — | — | $370.9m | $498.9m | $774.5m | — | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | — | $298.5m | $950k | $0 | — | — | $293.1m | ($293.1m) | |
| Net Cash Provided by (Used in) Investing Activities | ($36.0m) | ($86.4m) | ($413.5m) | ($157.9m) | ($34.7m) | ($81.9m) | ($216.7m) | $268.7m | ($189.9m) | $4.1m | ($14.7m) | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | ($671k) | ($295k) | — | $0 | — | — | — | — | — | — | — | |
| Proceeds from Issuance of Common Stock | $2.1m | $5.7m | $11.6m | $3.9m | $4.4m | $7.1m | $12.4m | $6.6m | $14.9m | $37.6m | $50.1m | |
| Net Cash Provided by (Used in) Financing Activities | $2.1m |
$5.7m
+176.85%
|
$376.4m
+6526.26%
|
$3.9m
-98.96%
|
$3.6m
-9.39%
|
($130.4m)
-3764.51%
|
($10.5m)
+91.97%
|
($397.9m)
-3697.65%
|
$12.2m
+103.06%
|
$9.1m
-25.12%
|
$31.5m
+245.12%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | $33.9m | $91.9m | ($10.9m) | $107.3m | ($85.2m) | ($110.3m) | ($18.1m) | ($5.7m) | $60.6m | $181.4m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $33.9m | $192.2m | $181.4m | $288.6m | $203.4m | $93.1m | $75.1m | $69.3m | $129.9m | $181.4m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | — | $4.3m | $6.8m | $34.9m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $493k | $134k | $1.3m | $2.5m | $2.5m | $2.5m | $2.5m | $1.9m | $0 | $0 | — | |
| Income Taxes Paid, Net | — | $1.6m | $34.8m | $51.5m | $45.4m | $25.2m | $16.2m | $36.6m | $53.3m | $16.1m | — | |
| Additional Financial Items | ||||||||||||
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | $0 | — | — | — | — | — | — | — | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | $448k | $76k | — | — | — | — | — | — | — | — | — | |
| Goodwill | — | — | — | — | $77.9m | $117.5m | $117.0m | $117.0m | $117.0m | $124.9m | $61.2m | |
| Income Tax Expense (Benefit) | ($40.9m) | $43.3m | $29.2m | $34.4m | $41.7m | $19.8m | $32k | $1.5m | $24.0m | ($10.5m) | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | $2.4m | $0 | $0 | — | |
| Investment Income, Interest | $1.5m | $2.9m | $13.8m | — | — | — | — | — | — | — | — | |
| Unrealized Gain (Loss) on Derivatives | $448k | $76k | — | $0 | ($1.9m) | $6.5m | — | — | — | — | — |